MedTrace Logo

Phase 1 Study of JLP-2302 and JP-1366: PK and Safety in Healthy Volunteers

NCT07181538 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 55

Last updated 2025-09-18

No results posted yet for this study

Summary

This study aims to evaluate the pharmacokinetics and the safety after administration of "JLP-2302" and "JP-1366" in healthy volunteers.

Conditions

  • Healthy

Interventions

DRUG

JLP-2302

taking JLP-2302

DRUG

JP-1366

taking JP-1366

Sponsors & Collaborators

  • Onconic Therapeutics Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-02-04
Primary Completion
2025-02-20
Completion
2025-03-05

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07181538 on ClinicalTrials.gov